Medexus Pharmaceuticals Inc.

MDP

CA58410Q2036

Pharmaceuticals

Market Closed - Toronto S.E. Other stock markets 03:39:39 2024-04-23 pm EDT			5-day change	1st Jan Change
1.65 ^CAD	+1.85%		+7.14%	-33.20%

Mar. 26	Medexus Pharmaceuticals Announces US Food and Drug Administration Approves It's Supplemental Biologics License Application for IXINITY(R)	CI
Feb. 09	Medexus Pharmaceuticals Maintained at Speculative Buy at Stifel GMP After Fiscal Q3 Miss; Price Target Cut to C$2.85	MT

Medexus Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended March 31, 2021

June 16, 2021 at 05:31 pm EDT

Medexus Pharmaceuticals Inc. announced earnings results for the full year ended March 31, 2021. For the full year, the company announced operating loss was USD 1.376 million compared to USD 5.789 million a year ago. Net loss was USD 28.264 million compared to USD 4.701 million a year ago. Basic loss per share from continuing operations was USD 1.86 compared to USD 0.33 a year ago.

Latest news about Medexus Pharmaceuticals Inc.

Medexus Pharmaceuticals Announces US Food and Drug Administration Approves It's Supplemental Biologics License Application for IXINITY(R)	Mar. 26	CI
Medexus Pharmaceuticals Maintained at Speculative Buy at Stifel GMP After Fiscal Q3 Miss; Price Target Cut to C$2.85	Feb. 09	MT
Medexus Pharmaceuticals Down 30% After Announces Fiscal Q3 2024 Results	Feb. 08	MT
Medexus Pharmaceuticals Announces Fiscal Q3 2024 Results	Feb. 08	MT
Transcript : Medexus Pharmaceuticals Inc., Q3 2024 Earnings Call, Feb 08, 2024	Feb. 08
Medexus Pharmaceuticals Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	Feb. 07	CI
North American Morning Briefing : Stock Futures Hold Line Ahead of More Earnings, Fedspeak	Feb. 07	DJ
Medexus Pharmaceuticals Says Health Canada to Review New Drug Submission for Topical Terbinafine	Jan. 08	MT
Medexus Pharmaceuticals Announces Health Canada Accepts for Review Medexus's New Drug Submission, or NDS, for Terbinafine Hydrochloride Nail Lacquer to Treat fungal N Infections	Jan. 08	CI
Transcript : Medexus Pharmaceuticals Inc., Q2 2024 Earnings Call, Nov 09, 2023	Nov. 09
Medexus Pharmaceuticals Inc. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	Nov. 07	CI
Medexus Pharmaceuticals Closes $10 Million Bought Deal Financing	23-10-06	MT
Medexus Pharmaceuticals and Medac GmbH Agree to Amend US Treosulfan Agreement	23-09-28	CI
Medexus Pharmaceuticals Announces C$10 Million Bought-Deal Public Offering of Units	23-09-06	MT
North American Morning Briefing : Inflation Worries Push Stock Futures Lower	23-09-06	DJ
Medexus Pharmaceuticals Announces the Presentation of Data from Phase 3/4 Study to Evaluate the Pharmacokinetics, Safety, and Efficacy of IXINITY	23-08-17	CI
Transcript : Medexus Pharmaceuticals Inc. - Special Call	23-08-14
Transcript : Medexus Pharmaceuticals Inc., Q1 2024 Earnings Call, Aug 10, 2023	23-08-10
Medexus Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended June 30, 2023	23-08-09	CI
Medexus Jumps Near 14% As Swings To Fiscal Q4 Net Income YOY	23-06-22	MT
Transcript : Medexus Pharmaceuticals Inc., Q4 2023 Earnings Call, Jun 22, 2023	23-06-22
Medexus Swings To Fiscal Q4 Net Income YOY	23-06-22	MT
Medexus Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended March 31, 2023	23-06-21	CI
Medexus Pharmaceuticals Presents Positive New Data on Treosulfan That Researchers At Toronto's Princess Margaret Hospital Recently Presented At Mds 2023	23-06-13	CI
Medexus Forecasts Record Revenue for Fiscal Year 2023, Appoints New Board Chair	23-04-11	MT

Chart Medexus Pharmaceuticals Inc.

Duration

Period

More charts

Company Profile

Medexus Pharmaceuticals Inc. is a Canada-based specialty pharmaceutical company with a North American commercial platform. The Company has a portfolio of rare disease treatment solutions. The Company is focused on the therapeutic areas of oncology, hematology, rheumatology, auto-immune diseases, allergy and dermatology. The Company has two divisions: Medexus Pharma Canada and Medexus Pharma USA. Medexus Pharma Canada division is a fully integrated commercial infrastructure focused on rheumatology, allergy, auto-immune disease, specialty oncology and pediatric diseases in Canada. The divisionâs prescription products include Metoject (Methotrexate Injection), Rupall (Rupatadine), Cuvposa (Glycopyrrolate Oral Solution), Pediapharm Naproxen Suspension (Naproxen) and others. Medexus Pharma USA division is a fully integrated commercial infrastructure focused on rheumatology and auto-immune diseases in the United States. The divisionâs products include Rasuvo, IXINITY and Gleolan.

Sector

Pharmaceuticals

Calendar

2024-06-18 - Q4 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Medexus Pharmaceuticals Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

1.62 CAD

Average target price

3.208 CAD

Spread / Average Target

+98.05%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
MEDEXUS PHARMACEUTICALS INC.	-33.20%	28.87M
ELI LILLY AND COMPANY	+27.92%	659B
NOVO NORDISK A/S	+27.68%	557B
JOHNSON & JOHNSON	-4.59%	359B
MERCK & CO., INC.	+16.38%	322B
ABBVIE INC.	+9.39%	297B
ASTRAZENECA PLC	+6.30%	215B
NOVARTIS AG	+4.80%	210B
ROCHE HOLDING AG	-6.05%	200B
PFIZER, INC.	-8.58%	149B

Other Pharmaceuticals